Despite the encouraging results from sunitinib trial in improving hearing and tumor shrinkage in some NF2 patients with progressive vestibular schwannomas, treatment with bevacizumab, a drug specifically targeting VEGFR, did not result in clinically significant response in meningiomas. The gene discussed is KDR; the disease is meningioma.